“…[9,10] The synthesis and use of well-defined glycoprotein therapeutics and glycovaccines-uniform in sugar, site, and level of protein attachment-is rare and most constructs are prepared and administered as complex mixtures. [4,6,7,11,12] Given the unknown influence of conjugation site on immunogenic response, it is remarkable that, to our knowledge, no homogeneous glycovaccine has been studied. [4,6,7,11,12] Given the unknown influence of conjugation site on immunogenic response, it is remarkable that, to our knowledge, no homogeneous glycovaccine has been studied.…”